Piper Sandler analyst Adam Maeder raised the firm’s price target on Silk Road Medical to $18 from $11 and keeps a Neutral rating on the shares. The firm notes Silk Road Medical reported Q4 results, including sales of $47.3M, which came in ahead of the Street’s $42.1M bogey. Additionally, the company guided to full year 2024 revenue of $194M-$198M, which came in slightly above Street expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook
- SILK Earnings this Week: How Will it Perform?
- Silk Road Medical participates in a conference call hosted by Lake Street
- Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Silk Road Medical upgraded to Buy from Hold at Stifel